Pharmacology of botulinum toxin drugs; [Pharmakologie der botulinumtoxinmedikamente]

被引：0
作者：
Dressler D. [1 ]
机构：
[1] Bereich Bewegungsstörungen, Klinik für Neurologie, Medizinische Hochschule Hannover, 30625 Hannover
来源：
HNO | 2012年 / 60卷 / 6期
关键词：
Antigenicity; Botulinum toxins; Complexing proteins; Pharmaceutical preparation; Therapeutic use;
D O I：
10.1007/s00106-012-2494-1
中图分类号：
学科分类号：
摘要：
Botulinum toxin (BT) is used with remarkable success to treat various disorders caused by muscle hyperactivities or exocrine gland over activity. Its use for treatment of non-muscular pain conditions is currently being explored. In Germany, BT type A is available as Botox ®, Dysport ® and Xeomin ®, BT type B as NeuroBloc ®. In aesthetic medicine they are called Vistabel ®, Azzalure ® and Bocouture ®. Numerous other BT drugs are used worldwide. Often, their origin is dubious. BT drugs consist of botulinum neurotoxin, complexing proteins and adjuvants. Their manufacturing process is highly complex. BT drugs vary in many aspects. By no means are they generics. Clinically relevant differences include their potency labeling, antigenicity, presence of complexing proteins, storage conditions, pH value of the reconstituted drug and pharmaceutical preparation. © Springer-Verlag 2012.
引用
收藏
页码：496 / 504
页数：8
相关论文
共 56 条
[1]  
Antonucci F., Rossi C., Gianfranceschi L., Et al., Long-distance retrograde effects of botulinum neurotoxin, A J Neurosci, 28, pp. 3689-3696, (2008)
[2]  
Aurora S.K., Dodick D.W., Turkel C.C., Et al., Onabotulinumtoxin A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial, Cephalalgia, 30, pp. 793-803, (2010)
[3]  
Benecke R., Jost W.H., Kanovsky P., Et al., A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia, Neurology, 64, pp. 1949-1951, (2005)
[4]  
Binz T., Blasi J., Yamasaki S., Et al., Proteolysis of SNAP-25 by types E and A botulinal neurotoxins, J Biol Chem, 269, pp. 1617-1620, (1994)
[5]  
Brin M.F., Dressler D., Aoki R., Pharmacology of botulinum toxin therapy, Dystonia: Etiology, Clinical Features, and Treatment, (2004)
[6]  
Cui M., Li Z., You S., Et al., Mechanisms of the anti nociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing, Arch Pharmacol, 365, (2002)
[7]  
de Paiva A., Meunier F.A., Molgo J., Et al., Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals, Proc Natl Acad Sci USA, 96, pp. 3200-3205, (1999)
[8]  
Diener H.C., Dodick D.W., Aurora S.K., Et al., Chronic migraine study group. Onabotulinumtoxina for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial, Cephalalgia, 30, pp. 804-814, (2010)
[9]  
Dressler D., Routine use of Xeomin® in patients pre-treated with Botox®, Eur J Neurol, 16, SUPPL. 2, pp. 2-5, (2009)
[10]  
Dressler D., Subclinical myasthenia gravis causing increased sensitivity to botulinum toxin therapy, J Neural Transm, 117, pp. 1293-1294, (2010)
123456